Allergan is a $23 billion diversified global pharmaceutical company and a leader in a new industry model - Growth Pharma. The company is anchored by strong and sustainable brand franchises, a leading global generics business, a premier pipeline, highly efficient operations and an experienced management team creating an unrivaled foundation for long-term growth.
The Company has more than 20 innovative products in near- or mid-term development and is strategically focused within its core therapeutic areas, with key candidates in Dermatology and Aesthetics, Eye Care, CNS, GI, Anti-infectives, Women’s Health and Urology.
Supporting these blockbuster franchises is the company’s industry-leading U.S. sales force with extraordinary marketing reach and increased relevance with primary care physicians and specialists.
The Company’s generics pipeline is also positioned to deliver sustainable growth, with approximately 230 Abbreviated New Drug Applications pending at FDA, including approximately 70 first-to-file applications, as well as nearly 1,000 marketing authorization applications filed outside of the U.S. in 2014.
Research and Development
Together, our Company is focused on developing new medicines that address unmet medical needs in critical therapeutic areas, as well as increasing global access to high-quality, affordable medicines.
Driving continued innovation and growth is the combined company’s strong commitment to R&D, with an investment of ~$1.7 billion in 2015, focused on the strategic development of innovative and durable value-enhancing products within brands, generics, biologics, and OTC portfolios.
The Company’s Generics portfolio features more than 1,000 generics, branded generics, established brands, and OTC products. The Company is the third largest generic manufacturer in the U.S. and holds a top 5 leadership position in nearly 20 International markets.
Allergan has global headquarters in Dublin, Ireland and U.S. Administrative Headquarters in Parsippany, New Jersey, USA.
Copyright © 2017-2021 Great Peel. All rights reserved